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Abstract
Heme oxygenase (HO) catalyzes the rate-limiting step in the O2-
dependent degradation of heme to biliverdin, CO, and iron with 
electrons delivered from NADPH via cytochrome P450 reductase 
(CPR). Biliverdin reductase (BVR) then catalyzes conversion of bili-
verdin to bilirubin. We describe mutagenesis combined with kinetic, 
spectroscopic (fluorescence and NMR), surface plasmon resonance, 
cross-linking, gel filtration, and analytical ultracentrifugation studies 
aimed at evaluating interactions of HO-2 with CPR and BVR. Based 
on these results, we propose a model in which HO-2 and CPR form 
a dynamic ensemble of complex(es) that precede formation of the 
productive electron transfer complex. The 1H-15N TROSY NMR 
spectrum of HO-2 reveals specific residues, including Leu-201, near 
the heme face of HO-2 that are affected by the addition of CPR, im-
plicating these residues at the HO/CPR interface. Alanine substitu-
tions at HO-2 residues Leu-201 and Lys-169 cause a respective 3- 
and 22-fold increase in Km values for CPR, consistent with a role for 
these residues in CPR binding. Sedimentation velocity experiments 
confirm the transient nature of the HO-2·CPR complex (Kd = 15.1 
μm). Our results also indicate that HO-2 and BVR form a very weak 
complex that is only captured by cross-linking. For example, under 
conditions where CPR affects the 1H-15N TROSY NMR spectrum of 
HO-2, BVR has no effect. Fluorescence quenching experiments also 
suggest that BVR binds HO-2 weakly, if at all, and that the previously 
reported high affinity of BVR for HO is artifactual, resulting from the 
effects of free heme (dissociated from HO) on BVR fluorescence. 
Keywords: Cytochrome P450, Electron Transfer Complex, Enzyme 
Kinetics, Enzyme Mechanism, Heme Oxygenase, Nuclear Magnetic 
Resonance (NMR), Protein/Protein Interaction
Precise regulation of heme metabolism is crucial for the cell. Heme is an active catalyst for generating reactive oxygen 
species by Fenton chemistry and is cytotoxic at elevated levels 
(above ~1 μm) (1). Heme is also a required prosthetic group 
for many proteins involved in electron transfer, oxygen trans-
port, and redox enzymology (e.g. oxidases) (2). The mamma-
lian heme degradation pathway consists of two enzymatic 
steps, which are mediated by heme oxygenase (HO)4 and bili-
verdin reductase (BVR) (Figure 1). Cytochrome P450 reductase 
(CPR) is required as an electron donor for HO catalysis. HO is 
the only known catalyst in the mammalian cell that degrades 
heme (Reaction 1). HO catalyzes the conversion of heme to 
biliverdin in a reaction that requires O2, NADPH, and CPR, 
which transfers seven electrons as shown in Reaction 1 (3, 4). 
BVR then converts biliverdin to bilirubin (Reaction 2), which 
undergoes conjugation with glucuronate and is excreted from 
the body. 
In addition to protecting the cell from the toxicity of free 
heme, the heme degradation pathway generates biologi-
cally important products. The HO reaction is the only cellular 
source of CO, and although high levels of CO are toxic (>500 
ppm), at low levels, CO acts as a signaling molecule akin to 
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Background: Heme oxygenase, cytochrome P450 reductase, and biliverdin reductase are the key enzymes in heme degradation.
Results: Specific electrostatic and hydrophobic interactions form the binding interface between heme oxygenase and cytochrome P450 
reductase.
Conclusion: Heme oxygenase binds cytochrome P450 reductase dynamically and biliverdin reductase very weakly.
Significance: Characterizing interactions among proteins involved in heme degradation are crucial to understanding heme homeostasis.
heme + 7e– + 3O2  → biliverdin + CO + Fe(II) + 3H2O
Reaction 1
biliverdin + 2e– → bilirubin
Reaction 2
Abbreviations: HO, heme oxygenase; CPR, cytochrome P450 reductase; BVR, biliverdin reductase; TROSY, transverse relaxation-optimized spectros-
copy; SPR, surface plasmon resonance; LC-SPDP, succinimidyl 6-(3-[2-pyridyldithio]-propionamido)hexanoate; CPM, 7-diethylamino-3-(4′-maleimidylphenyl)-4-
methylcoumarin; CSP, chemical shift perturbation; Ni-NTA, nickel-nitrilotriacetic acid; PDB, Protein Data Bank; SPR, surface plasmon resonance
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NO (5, 6) and is cytoprotective (7). The release and recycling of 
iron from heme is critical for iron homeostasis as most of the 
iron required for the synthesis of new ferroproteins and heme 
comes from recycled iron, with less than 3% of the daily iron 
requirement derived from the diet (2, 8). Finally, the HO sys-
tem protects cells against oxidative stress, both by controlling 
free heme levels and by producing bilirubin, a potent antioxi-
dant (9–11). 
The heme degradation pathway affects many areas of cellu-
lar health as follows: heme and iron homeostasis, antioxidant 
protection, and gaseous signaling. As such, it is crucial to un-
derstand the mechanisms that regulate the activity of HO. 
HO exists as two major isoforms, HO-1 and HO-2. HO-3 
has also been described; however, it has low catalytic activity, 
and its biologic role and relevance are uncertain (12, 13). HO-1 
and HO-2 share a high degree of homology (55% identity and 
76% similarity) and display similar enzymatic activity (14). 
The two isoforms, however, have distinct patterns of expres-
sion and regulation. HO-1 is transcriptionally regulated and is 
expressed in most tissues, whereas HO-2 is constitutively ex-
pressed in a narrow range of tissues, primarily the brain and 
testes (15). Both HOs possess C-terminal membrane-spanning 
regions that tether them to the endoplasmic reticulum. How-
ever, because of poor solubility of the full-length protein, most 
enzymatic studies (as those described in this paper) have been 
conducted with a stable soluble form of HO lacking the C-ter-
minal region. A major difference between the two HOs is that 
HO-2 contains three heme regulatory motifs, consisting of a 
Cys-Pro dyad, whereas HO-1 completely lacks cysteines (16). 
Two of these heme regulatory motifs are at the C terminus of 
HO-2, just preceding the membrane-spanning section. When 
these are in the dithiol state, the affinity of HO-2 for heme (rel-
ative to the disulfide state) decreases significantly, suggest-
ing that the heme regulatory motifs act as a redox switch that 
controls activity in response to changes in cellular redox poise 
(17–19). 
Electrons are transferred to HO from NADPH via the ~77-
kDa dual flavin enzyme CPR through a pathway that involves 
its bound cofactors, FAD and FMN (20–23). In the cell, CPR is 
tethered to the endoplasmic reticulum by an N-terminal mem-
brane-spanning region. Protein/protein interactions between 
the soluble forms of HO-1 and CPR and between HO-1 and 
BVR have been described in vitro (24–27) and are an aspect 
of regulation that has not been addressed for HO-2. CPR also 
forms electron transfer complexes with the cytochromes P450, 
cytochrome b5, cytochrome c, and squalene monooxygenase 
(23, 28–31). Interactions with CPR may help define distinct 
roles for the HO isoforms. For example, recent reports suggest 
that binding of HO-1 and CPR regulates HO-1 nuclear translo-
cation and the transcriptional regulatory response under hy-
poxia by stabilizing the endoplasmic reticulum-tethered form 
of HO-1 in the cell (32). However, HO-2 appears to remain sta-
bly associated at the endoplasmic reticulum irrespective of hy-
poxic challenge (32). 
The complex between the soluble forms of CPR and HO-1 
(lacking their membrane-spanning regions) has been charac-
terized by fluorescence quenching (27), surface plasmon reso-
nance (SPR) (24), and acetylation protection assays (25). These 
reports provide Kd values for the HO-1· CPR complex that 
range from 0.4 ± 0.1 to 2.4 ± 0.6 μm. CPR protects lysine res-
idues 149 and 153 in HO-1 from chemical modification, sug-
gesting that these basic residues are at the interface of the HO-
1· CPR complex (25). Additionally, SPR studies indicate that 
the K149A substitution results in an ~10-fold increase in Kd for 
the HO-1· CPR complex (24). Although the HO-1· CPR com-
plex has been relatively well characterized, the HO-2· CPR 
complex has not. 
BVR catalyzes the second step in heme degradation, i.e. the 
reduction of biliverdin to bilirubin (Reaction 2). BVR is a sol-
uble ~33-kDa protein that utilizes two electrons from either 
NADH or NADPH making it unique to have dual cofactor 
specificity at distinct pH values (33). In addition to its canoni-
cal enzymatic function, BVR has also been shown to bind and 
traffic heme to the nucleus where it regulates HO-1 expression 
(34–37). Also, BVR is a dual specificity (Ser/Thr and Tyr) ki-
nase, and as such it is implicated in mitogen-activated protein 
kinase (MAPK) cell signaling pathways (38, 39). 
Two groups have reported interactions between HO-1 and 
BVR via fluorescence quenching studies and SPR (24, 27). The 
fluorescence quenching studies suggest a high affinity HO-
1·BVR complex (Kd = 0.2 μM) is formed, whereas SPR stud-
ies report that BVR competes with CPR for binding to HO-1. 
However, studies that identified the HO-1/CPR interface via 
lysine acetylation protection assays failed to find evidence for 
an HO-1/BVR interaction (25). Under single turnover condi-
tions, the rate-limiting step of the HO-1 reaction is the release 
of biliverdin; however, in the presence of BVR, this step is ac-
celerated (40), which indicates kinetic coupling between these 
two enzymes. Thus, although some evidence supports the for-
mation of a high affinity complex between HO-1 and BVR, 
Figure 1. Heme degradation pathway. The two enzymatic steps of heme degradation mediated by heme oxygenase and biliverdin reductase. HO converts 
heme to biliverdin, and BVR converts biliverdin to bilirubin. The HO reaction requires electrons transferred from NADPH via cytochrome P450 reductase (PDB 
1AMO, 2QPP, and 2H63). 
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other evidence challenges it. Furthermore, to our knowledge, 
the extent to which HO-2 is able to interact with BVR has not 
been addressed. Protein/protein interactions between HO and 
its reaction partners may play an important role in regulating 
its various properties, including cellular localization and en-
zymatic activity. Furthermore, given that they exhibit differ-
ent modes of transcriptional regulation, HO-1 and constitutive 
HO-2 may differ in their affinity for BVR and CPR. 
To gain insight into the protein level mode of regulating 
HO-2 activity, and to resolve some of the discrepancies related 
to measured interactions (or lack thereof) of HO-1 and HO-2 
with their binding partners, we have performed nuclear mag-
netic resonance (NMR), kinetic, analytical ultracentrifugation, 
gel filtration, cross-linking, SPR, and fluorescence quenching 
studies. Our experiments indicate that both HO-1 and HO-2 
form complexes with CPR. The interaction between HO-2 and 
BVR, however, is weak as compared with CPR, and it can only 
be detected by irreversible methods such as cross-linking. Our 
results allow us to propose an interface for the HO-2· CPR 
complex near the heme-binding face of HO-2 that includes res-
idues Leu-201 and Lys-169. Furthermore, our studies demon-
strate that the HO/CPR interface includes both hydrophobic 
and charge interactions. Our studies suggest a reinterpretation 
of protein/protein interactions in the heme degradation path-
way. We demonstrate that both HO-1 and HO-2 bind CPR in 
a transient electron transfer complex that is required for HO 
activity. However, interactions between BVR and HO-2 are 
weak to undetectable and may not play a significant role in the 
physiologic context of a cell. 
Experimental Procedures
Materials — Ampicillin, isopropyl β-d-thiogalactopyrano-
side, kanamycin, NADPH, NADP+, riboflavin, and hemin 
were purchased from Sigma. 7-Diethylamino-3-(4′-maleimi-
dylphenyl)-4-methylcoumarin (CPM) was purchased from 
Molecular Probes, Inc. (Eugene, OR). OneShot® BL21(DE3) 
chemically competent cells were purchased from Invitrogen. 
Nickel-nitrilotriacetic acid (NTA) resin was from Qiagen (Va-
lencia, CA). Glutathione-Sepharose was purchased from GE 
Healthcare. 
Enzymes — Truncated versions of human HO-1265 contain-
ing residues 1–265, and human HO-2288 containing residues 
1–288, and variants of these enzymes, were used in these stud-
ies. These enzymes lack the C-terminal amino acids that com-
prise their membrane anchors and will be referred to as HO-1 
and HO-2. To facilitate expression, solubility, and ease of puri-
fication, HO-1 was cloned into the expression vector pMCSG10 
by ligation-independent cloning (41). HO-2 was expressed and 
purified from the pET28a(+) vector. HO-1 and HO-2 were pu-
rified via an N-terminal His6 tag using Ni-NTA affinity chro-
matography according to the manufacturer’s guidelines (Qia-
gen, Valencia, CA). 
Human CPRΔ66 lacking the N-terminal membrane anchor 
was expressed from the pET28a(+) vector and is referred to 
as CPR for all studies described herein. CPR was expressed in 
BL21(DE3) cells and purified according to published methods 
(42). Human BVR was expressed from the pGEX-4T-2 vector 
and purified via glutathione-Sepharose affinity resin accord-
ing to the manufacturer’s instructions (GE Healthcare). 
Unless stated otherwise, affinity purification tags were re-
moved from all proteins by proteolysis before use in these ex-
periments. Tobacco etch virus protease (expressed in Esch-
erichia coli from pRK793, a derivative of BL21(DE3)-RIL, 
generously supplied by Dr. David S. Waugh at the Center for 
Cancer Research at NCI, National Institutes of Health) was 
used for HO-1, and thrombin was used for HO-2, CPR, and 
BVR. The affinity tags were separated from the protein by 
chromatography with the appropriate affinity resin (Ni-NTA 
for HO-1, HO-2, and CPR; and glutathione-Sepharose for 
BVR). All purification steps were performed at 4 °C. 
The cDNA for human full-length HO-1 was graciously sup-
plied by Dr. Ortiz de Montellano (University of California at 
San Francisco). The ligation-independent cloning expression 
vector pMCSG10 was donated by Dr. William Clay Brown 
(University of Michigan, Ann Arbor). Human full-length HO-2 
cDNA in a pGEX-4T-2 vector was generously contributed by 
Dr. Mahin D. Maines (University of Rochester, School of Med-
icine, Rochester, NY) and was subcloned into the pET28a(+) 
expression vector. CPR was kindly donated by Dr. Bettie Sue 
Masters (University of Texas Health Sciences Center, Arling-
ton, TX). The BVR gene was purchased from American Type 
Culture Collection (Manassas, VA) and subcloned into the 
pGEX-4T-2 plasmid. 
Site-directed Mutagenesis of HO-1 and HO-2 — Point mutations 
of HO-1 and HO-2 were constructed using the QuikChange 
site-directed mutagenesis protocol (Stratagene, La Jolla, CA). 
Oligonucleotides were synthesized by Integrated DNA Tech-
nologies (Coralville, IA). Positive transformants were enriched 
by antibiotic selection and confirmed using sequence analysis. 
All of the variants were purified exactly as described above for 
the wild type enzymes. 
NMR Samples — BL21(DE3) cells containing the pET28a(+)/
HO-2 plasmid were cultured in M9 minimal media with 1.0 
g/liter 15NH4Cl (Cambridge Isotopes, Tewksbury, MA) to 
achieve 15N labeling of the soluble HO-2 protein. HO-2 was 
purified as described above and loaded with heme by titra-
tion of freshly prepared hemin. Hemin stocks were prepared 
by solubilizing hemin in 15% dimethyl sulfoxide (DMSO), 0.1 
m NaOH, 50 mm Tris, pH 7.0. Hemin stocks were centrifuged 
at 17,000 × g for 10 min at 4 °C, and the supernatant was then 
passed through a 0.22-micron filter (Millipore, Billerica, MA) 
to remove insoluble matter. Hemin concentration was deter-
mined using an Σ385 nm of 58.44 mm
−1 (43). HO-2 was loaded 
with hemin by titrating small amounts of hemin and monitor-
ing the Soret peak at 404 nm until saturating levels of heme 
binding were achieved. NMR samples were prepared with 
150 μm heme-bound HO-2 in 50 mm Tris-HCl, pH 7.0, 50 mm 
KCl with 10% D2O in a total volume of 350 μl and placed in a 
Shigemi NMR tube. Experiments testing the ability of CPR or 
BVR to bind HO-2 were conducted with 150 μm HO-2 and the 
binding partner (BVR or CPR) at the indicated concentration. 
1H-15N apoHO-2 NMR TROSY samples were prepared 
identically to those described for hHO-2; however, heme was 
absent from the samples. 
For perdeuterated 15N-HO-2, samples were prepared as 
described above; however, BL21(DE3) cells were grown and 
induced in 2H2O/M9 minimal media. Electrospray ionization 
mass spectrometry analysis revealed label incorporation to 
be 99.8%. 
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1H-15N TROSY NMR Measurements — Two-dimensional 1H-
15N HSQC TROSY spectra were acquired on an Agilent/
Varian 800 MHz spectrometer equipped with a triple reso-
nance gradient (PFG) cryoprobe operating at 30 °C. Spectra 
were acquired using an array of 2404 × 300 complex points 
and with the spectral widths of 12019.2 and 2999.9 Hz for 
1H and 15N, respectively. All spectra were processed with 
NMRPipe software (44) and visualized using Sparky 3.114 
(45). Intensity analysis was conducted as described (46); the 
peak heights of chemical shifts were derived from Sparky 
and used to calculate the ratio of resonance height for the 
1H-15N HO-2 spectrum with and without CPR or BVR. The 
chemical shift perturbation (CSP) for the assigned cross-
peaks was measured between the 0 μm CPR spectrum and 
the 75 or 150 μm CPR spectrum for the perdeuterated 15N-
hHO-2 TROSY spectrum. CSPs were calculated from the 
square root of the sum of the squared N1H and 15N CSPs for 
each assigned cross-peak. 
NMR Relaxation —The experiments for studying the 15N 
NMR relaxation of HO-2 were carried out using a 40 μm HO-2 
sample that was 15N-labeled in 50 mm Tris-HCl, 50 mm KCl, 
pH 7.0, and recorded at 30 °C on a Agilent/Varian 800 MHz 
NMR system, using a cryoprobe. 
One-dimensional versions of the standard 15N R1 and 15N 
R2 HSQC experiments (with cross-correlation, but with with-
out Rex suppression) were carried out (47). In these experi-
ments, amide proton magnetization is transferred to the am-
ide 15N, where it is allowed to decay according to 15N R1 or R2 
relaxation mechanisms and transferred back to the amide pro-
ton for observation. R2 relaxation is faster for larger than for 
smaller molecules; R1 relaxation is slower for larger than for 
smaller molecules. From the ratio, one may calculate the rota-
tional correlation time. For spherical, rigid proteins, the rota-
tional correlation time is proportional to the molecular weight. 
The data were processed in NMRpipe and exported in text 
format using the Pipe2txt.tcl routine. The data were then im-
ported into Microsoft Excel. For each spectrum, the ranges 
8.7–9.0 ppm (structured core residues) were integrated, and 
the data were fit to a single exponential decay curve using in-
house written nonlinear least square fit code with jackknife er-
ror estimation (48). 
Steady-state Kinetic Analysis of HO-1, HO-2, and Variants — The HO 
enzymatic assay was modified from methods described previ-
ously (49, 50). Recent studies establish that catalase enhances 
the linearity of the membrane-bound HO-1-catalyzed reaction 
(50). In our soluble system, we found a similar benefit of cata-
lase for both HO-1 and HO-2 and therefore included it in the 
enzymatic assays. The 200-μl reaction contained 0.1 μm HO, 
15 μm heme, 0.35 μm BVR, 0.25 μg/μl BSA, 20 units/μl cat-
alase, and varying concentrations of CPR in reaction buffer 
(50 mm Tris-HCl, pH 8.0, 50 mm KCl). The reaction was incu-
bated at 37 °C for 2 min and then initiated with the addition of 
8 μl of 10 mm NADPH. Activity was monitored using a Shi-
madzu UV-2600 spectrophotometer by following the increase 
in bilirubin absorbance at 468 nm. The difference extinction 
coefficient between heme and bilirubin at 468 nm of 43 mm−1 
cm−1 was used. 
Size Exclusion Chromatography — For gel filtration experiments, 
proteins were dialyzed into buffer containing 50 mm Tris-HCl, 
pH 7.0, 50 mm KCl. After recovery from the dialysis tubing, 
samples were prepared with 50 μm of the indicated protein, 
150 μm heme, and 150 μm NADP+. Gel filtration was con-
ducted with a Shimadzu HPLC with an LC-10AT pump sys-
tem using a Shodex KW-803 column (Shodex, Torrance, CA). 
The column was calibrated using gel filtration standards (Bio-
Rad), and the void volume was determined using blue dextran 
(2000 kDa, Sigma). 
Surface Plasmon Resonance with HO and CPR — SPR binding ex-
periments were conducted using a BIAcore 2000 (GE Health-
care) at 25 °C in 50 mm Tris, pH 7.0, 50 mm KCl with 0.005% 
surfactant p20. HO-1 or HO-2 was immobilized directly to the 
dextran matrix of a research grade CM5 sensor chip by amine 
coupling according to the manufacturer’s instructions (GE 
Healthcare). The sensor chip surface was activated with NHS/
EDC for 7 min. Immobilized proteins were diluted to 0.001 
μg/μl with 10 mm sodium acetate, pH 4.5, and injected over 
the sensor chip surface. To minimize nonspecific binding and 
mass transfer, the immobilization levels were kept below 1000 
response units. HO-1 and HO-2 were immobilized to 900 and 
300 response units, respectively. 
For kinetic analysis of CPR and HO, 45 μl of varying con-
centrations of CPR were injected at a flow rate of 20 μl/min. 
Chip regeneration was conducted with a 5-μl injection of 0.5 
mm NaCl. A blank reference cell was subtracted from the ex-
perimental data. To determine kinetic parameters, three in-
dependent experiments were initially analyzed using BIAe-
valuation software (GE Healthcare) and fit to a 1:1 Langmuir 
binding model or a bivalent analyte model. Because these 
models fit the data poorly, the association phase of CPR bind-
ing to HO was analyzed using single exponential fits (Graph-
Pad 6.0). Kinetic constants were determined from the linear re-
gression of kobs values plotted against CPR concentration. 
For experiments with immobilized CPR, human CPR was 
immobilized to the CM5 chip according to previously de-
scribed methods for immobilization of rat CPR (24). Briefly, 
CPR was immobilized via thiol groups of cysteine resi-
dues with the coupling reagent 2-(2-pyridinyldithio)etha-
neamine). To stabilize the enzyme and protect residues near 
the NADPH-binding site, NADPH was included during the 
immobilization of CPR. CPR was immobilized to ~2000 re-
sponse units. Others have reported that modification of CPR 
by 2-(2-pyridinyldithio)ethaneamine) does not affect enzyme 
activity (24). Binding analysis with immobilized CPR was per-
formed identically to those described above, with freshly pre-
pared hemin as the soluble analyte. 
Sedimentation Velocity Analysis — Binding interactions between 
HO-2 and CPR were analyzed by sedimentation velocity ex-
periments using a method described previously (51). Sedi-
mentation velocity experiments were performed on an Op-
tima XL-I analytical ultracentrifuge (Beckman Coulter, Inc.) 
equipped with an eight-hole An50Ti rotor. Prior to analysis, 
HO-2 and CPR were dialyzed against 50 mm Tris, pH 8.0, con-
taining 150 mm NaCl. CPR (20.5 μm) was then mixed with in-
creasing concentrations of HO-2 (0–55 μm), and the resulting 
protein mixtures (400 μl) were loaded into the sample com-
partment of a double-sector cell. The reference compartment 
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was filled with 430 μl of the dialysate buffer. Sample cells were 
then incubated at 20 °C in the rotor chamber for 2 h under vac-
uum. After 2 h of incubation, samples were sedimented at 
40,000 rpm. A total of 180 absorbance scans (450 nm) at 3-min 
intervals were collected. Absorbance values ranged from 0.2 to 
0.8 for the different samples. The data were analyzed by SED-
FIT version 10.58d (52) using the continuous c(s) distribution 
model and allowing the frictional ratio to float. CPR-/HO-2 in-
teractions were monitored by integrating the c(s) distribution 
between 4 and 7 S to determine the weight-average s value of 
the new observed boundary component (51). A Kd value for 
the CPR·HO-2 complex was estimated by plotting the weight-
average s value as a function of HO-2 and fitting the data to a 
single-site binding isotherm. 
Chemical Cross-linking — The reducible, heterobifunctional 
cross-linker (succinimidyl 6-(3-[2-pyridyldithio]-propion-
amido)hexanoate) (LC-SPDP) was used in a two-step reac-
tion according to the manufacturer’s instructions (Thermo 
Scientific/Pierce). HO-1 or HO-2 was activated as follows. A 
fresh 3 mm solution of LC-SPDP was prepared in DMSO. 10 
μm HO-1 or HO-2 was prepared in conjugation buffer (0.1 m 
HEPES), pH 7.5, 30 mm EDTA, 150 mm NaCl and incubated 
with 0.1 mm LC-SPDP for 30 min at room temperature. Un-
conjugated cross-linker was then removed by three rounds 
of buffer exchange using 10,000 molecular weight cutoff Am-
icon microconcentrators (Millipore, Billerica, MA). 10 μm 
BVR, CPR, or RNase was then added to the activated protein, 
and the reaction was incubated at 4 °C overnight. Cross-link-
ing reactions were analyzed by 5–15% gradient sodium SDS-
PAGE (Bio-Rad) and visualized by staining the gel with Coo-
massie Blue (53). 
Co-purification of BVR with HO-2 — For the co-purification of 
BVR with HO-2, the cross-linking reaction was performed ex-
actly as described above; however, HO-2 contained an N-ter-
minal His6 tag (hisHO-2) that was absent in the other reac-
tions. By SDS-PAGE, the cross-linked products of the reaction 
containing hisHO-2 and BVR migrated to identical positions 
as those in which the His6 tag had been removed from HO-
2. Samples of hisHO-2 alone, BVR alone, or cross-linked 
hisHO-2/BVR were incubated with 100 μl of Ni-NTA resin 
(50% slurry) for 2 h at 4 °C. Samples were rotated on a Boekel 
variable speed mini-tube rotator (Fisher). Affinity resin and 
associated proteins were harvested by centrifugation for 5 
min at a setting of 2400 × g at 4 °C with an accuSpin Micro 
17R refrigerated microcentrifuge (Fisher) and washed three 
times with 1 ml of wash buffer (50 mm Tris-HCl, pH 8.0, 30 
mm NaCl, 20 mm imidazole). Protein bound to the resin was 
eluted with 50 mm Tris-HCl, pH 8.0, 30 mm NaCl, 300 mm im-
idazole. Eluted fractions were boiled for 5 min in SDS-PAGE 
loading buffer (50 mm Tris-HCl, pH 6.8, 2% (w/v) SDS, 0.1% 
(w/v) bromphenol blue, 10% (v/v) glycerol, and 100 mm di-
thiothreitol) and separated by 10% SDS-PAGE (53). Proteins 
were then transferred to a nitrocellulose membrane and de-
tected using antibodies against either HO-2 (18) or BVR (Ab-
cam, Cambridge, MA). 
Modification of BVR with CPM — Human BVR was modi-
fied with 7-diethylamino-3-(4′-maleimidylphenyl)-4-methyl-
coumarin (CPM) according to methods used to modify rat 
BVR (27). A 20 mm solution of CPM was prepared in dimethyl 
sulfoxide. 10 μm BVR with 1 mm NADPH was incubated in 
the dark with 100 μm CPM at 4 °C for 16 h. Free CPM was 
removed using a PD-10 desalting column (Amersham Biosci-
ences). Labeled BVR was then frozen and stored in the dark at 
−80 °C. BVR-CPM was analyzed by LC MS/MS to determine 
the location of the CPM modification. 
Fluorescence Resonance Energy Transfer (FRET) Analysis of the Inter-
action of HO-1 or HO-2 with BVR — FRET experiments to examine 
HO-1 or HO-2 binding to human BVR were conducted accord-
ing to previously described methods for rat BVR (27). Briefly, 
because the UV-visible spectra of heme-bound HO-1 and 
HO-2 overlap the fluorescence emission spectrum of the fluo-
rescent probe CPM, binding of heme-bound HO should result 
in fluorescence quenching of BVR-CPM. BVR-CPM (0.05 μm) 
was titrated with various concentrations of heme-bound HO-
1, heme-bound HO-2, or heme, and fluorescence was moni-
tored at 450 nm with excitation at 350 nm. These experiments 
were performed in 0.1 m potassium phosphate buffer at pH 
7.4 on a Shimadzu FR-5301PC spectrofluorophotometer. 
Heme Binding BVR by Optical Absorbance — To obtain the absor-
bance spectrum of heme-BVR, the difference spectra between 
350 and 700 nm were recorded for 2.5 μm BVR with 2.0 μm 
heme, whereas the reference cuvette contained 2.5 μm BVR 
alone. To determine binding affinity of heme for BVR, 10 μm 
hemin was titrated with increasing amounts of BVR (0.5–5.0 
μm) with 10 μm heme alone in the reference cuvette. Absor-
bance at 415 versus BVR concentration was fit to a single site 
binding model using GraphPad Prism 6.0. To assess the ability 
of BVR to bind heme from hHO-2, 5 μm of hHO-2 was incu-
bated with varying concentrations of BVR (1.0–20.0 μm), and 
the absorbance spectra from 250 to 700 nm was collected, with 
the reference cuvette containing 5 μm hHO-2. hHO-2 was pre-
pared by incubating apoHO-2 with a 5-fold excess of freshly 
prepared hemin for 1 h at 4 °C. Unbound heme was removed 
using a PD10 desalting column according to the manufactur-
er’s instructions (GE Healthcare). For all experiments fresh he-
min was used and was prepared as described above. All spec-
tra were collected on a Shimadzu UV-2600 spectrophotometer. 
Results
Various forms of HO and CPR lacking their transmem-
brane segments were used in these studies. These are HO-1(1–
265) containing residues 1–265, HO-2(1–288), and CPR(66–
680). For clarity, these proteins will be referred to simply as 
HO-1, HO-2, or CPR. In experiments that use heme-bound 
HO, we refer to the protein as hHO-1 or hHO-2. 
NMR Analysis of the Interaction between hHO-2 and CPR — NMR 
is a highly sensitive method to probe protein/protein inter-
actions. Binding of an NMR-silent protein to an NMR-visi-
ble protein can perturb the spectrum in several ways; it can 
change the chemical shift, alter the line width of a resonance, 
or affect both chemical shift and line width. If resonances 
within the NMR spectrum have been assigned, these spectral 
changes can provide residue-specific information regarding 
the interface between the two proteins. 
We recently assigned 70% of the backbone chemi-
cal shifts of the hHO-2 (heme-bound) NMR spectrum by 
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three-dimensional NMR experiments using a highly concen-
trated sample (1 mm).5 To avoid potential nonspecific inter-
action effects that could arise with highly concentrated pro-
tein, in the binding studies described here, we used 150 μm 
15N hHO-2 samples. Because large proteins such as HO-2 
(~33 kDa) tend to exhibit faster transverse relaxation that re-
duces signal intensity of the NMR spectrum, we utilized trans-
verse relaxation-optimized spectroscopy (TROSY). TROSY is a 
method that reduces the 1H and 15N resonance line widths to 
enhance the spectra of larger proteins (>30 kDa) (54). By apply-
ing TROSY, we observe 211 cross-peaks in the 1H-15N TROSY 
spectrum of perdeuterated 15N-hHO-2, which accounts for res-
onances arising from ~70% of the hHO-2 residues (Figure 2). 
The hHO-2 spectrum consists of resonances arising from both 
ordered and disordered regions of the protein. Amide pro-
ton resonances arising from disordered regions of HO-2 occur 
in the 7.7–8.6 ppm range, which has a high density of over-
lapping peaks characteristic of poorly structured regions (46). 
This region of the spectrum corresponds to the flexible N- and 
C-terminal domains of hHO-2 residues 1–28 and 243–288. The 
well dispersed peaks outside of the disordered region arise 
from the core of hHO-2, as highlighted by the annotated spec-
tra (Figure 2). (I. Bagai, S. W. Ragsdale, and E. R. P. Zuider-
weg, manuscript in preparation.) Also, in the crystal struc-
ture of HO-2 (PDB 2QPP), only the catalytic core of the protein 
(residues 29–242) is visible, and both the N and C termini are 
not observed, further supporting the flexibility of the N and C 
termini (55). 
To probe the interface between hHO-2 and CPR, we col-
lected the spectrum of perdeuterated 15N-hHO-2 in the pres-
ence or absence of natural abundance CPR (lacking any label). 
As noted above, we used a lower concentration of hHO-2 (150 
μm) than was used earlier to make the assignments to mini-
mize the potential for nonspecific effects such as aggregation. 
We overlaid the assigned HO-2 spectrum with that collected 
in the binding studies to determine assignments for the spec-
trum in the binding studies. Using this method, ~50% of the 
288 HO-2 residues in the binding study could be assigned. 
Analysis of the HO-2 spectrum described below will focus on 
the assigned region of the protein. 
We measured the chemical shift and peak height for reso-
nances in the hHO-2 TROSY spectrum in the presence and ab-
sence of CPR. To identify hHO-2 residues that are affected by 
CPR, we compared the 1H-15N TROSY spectrum of hHO-2 in 
the presence of equimolar unlabeled CPR with that of hHO-2 
alone. The addition of CPR to hHO-2 causes changes in hHO-2 
chemical shifts and also decreases in peak intensities for a 
number of hHO-2 residues (Figure 2). This peak intensity loss 
is consistent with an increase in molecular weight and con-
comitant reduction of TROSY intensity that we would expect 
to occur as hHO-2 molecular weight increases with the bind-
ing of a 70-kDa protein such as CPR (46, 56). 
Figure 2. NMR analysis of CPR binding hHO-2. 1H-15N TROSY spectra of 150 μm perdeuterated 15N-hHO-2 collected in the absence (black) or presence 
(red) of equimolar CPR. 
29842 s p e n c e r e t  a l . i n t h e j o u r n a l  o f  b i o l o g i c a l  c h e m i s t ry  289 (2014) 
The addition of CPR to hHO-2 also results in CSPs for some 
hHO-2 cross-peaks (Figure 3). This demonstrates that the ki-
netics of binding is in the fast or intermediate fast exchange 
for which the resonance position ωi
obs of a certain residue i is 
given by Equation 1 (57), 
where ffree and fbound are the molar fractions of free and com-
plexed HO-2, and where ωi
free and ωi
bound are the chemical 
shifts in radians of that resonance in those states. Equation 1 
holds for both 1H and 15N dimensions in the TROSY spectrum. 
To quantify CSPs, the 1H and 15N chemical shift difference 
was calculated by comparing the chemical shifts of hHO-2 
alone with those of CPR. The combined 15N/NH chemical 
shift change was calculated as the chemical shift change vec-
tor as described under “Experimental Procedures.” Of the 47 
assigned cross-peaks in the N and C termini, none exhibit sig-
nificant CSPs with the addition of equimolar CPR; however, 
28 residues from the HO-2 core exhibit significant CSPs (Fig-
ure 4). Mapping the residues with significant CSPs onto the 
hHO-2 crystal structure highlights contiguous patches of resi-
dues on HO-2 that are likely involved in binding CPR or expe-
rience allosteric effects upon CPR binding (Figure 5). Equally 
important, there are also many assigned resonances that do 
not shift, and they also form contiguous patches. 
For the range 0.1 < ffree or fbound < 0.9, the line width, LWiobs, 
for a resonance i in the fast/intermediate exchange regime is 
given by Equation 2 (57). 
Here, the first two terms represent the increase in line 
width due to a change in the time-averaged molecular weight 
of HO-2, although the latter term, called exchange broadening, 
is excess broadening due to the kinetics of binding. 
The increase in line width causes a loss in TROSY cross-
peak height by two processes as follows: the first is a linear 
effect and occurs because a broader line in the spectrum has 
a lower peak height; the second is a strongly nonlinear effect 
due to a decrease in the coherence transfer efficiencies in the 
TROSY experiment itself. For large proteins that bind to other 
large proteins, the second effect is dominant. 
To quantify the peak intensity loss in the hHO-2 spectrum 
upon CPR binding, the peak intensity ratio was determined by 
dividing the cross-peak intensity in the presence of CPR by the 
cross-peak intensity from the hHO-2 alone spectrum (+CPR/−
CPR, Figure 6). A ratio of 1 indicates no effect, although a de-
creased ratio indicates line broadening for that resonance. 
Cross-peaks derived from residues located at the HO-2 N and 
C termini (residues 1–28 and 243–288) are largely unaffected 
by the addition of equimolar CPR; of the 47 assigned cross-
peaks, only four exhibit chemical shift intensity ratios of less 
than 0.8 (Gly-20, Ala-245, and Glu-247). This is in contrast to 
the 96 assigned cross-peaks located at the core of HO-2 (res-
idues 29–242); 88 resonances exhibit an intensity ratio of less 
than 0.8, and 23 have disappeared likely due to broadening be-
yond detection (Figure 6). Mapping the intensity ratios onto 
the hHO-2 crystal structure shows the residues that are most 
strongly affected by CPR are on the heme binding face of 
hHO-2 (in which the heme binding pocket and surrounding 
residues are visible), although residues on the opposite face 
(180° rotation) of hHO-2 are less affected (Figure 7). 
The interaction areas determined from intensity changes 
(Figure 5) and chemical shift changes (Figure 7) do overlap in 
general, suggesting the main binding area is identified by both 
Figure 3. Effect of CPR on hHO-2 chemical shifts. Detail of the 1H-15N hHO-2 spectrum with 0, 75, or 150 μm CPR (black, blue, and red, respectively) 
highlighting cross-peaks that experience significant perturbations of the chemical shift or significant intensity loss. Glu-182 and Asp-210 show highly significant 
change in chemical shifts, although Leu-81 is broadened beyond detection with the addition of CPR. x represents the center of the indicated cross-peak. Highly 
significant changes in CSP are greater than two standard deviations from the mean CSP for assigned residues. 
                          ωi
obs = ffree ωifree + fbound ωibound   (1)
LWi
obs =  ffree LWifree + fbound LWibound  
+ ffree  fbound  
 (ωi
free – ωi
bound)2                   (2)
                                                           (1 + fbound/ ffree)koff
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observables. However, the intensity changes and chemical 
shifts do not correlate per residue. The most compelling case 
occurs for the resonance of Leu-201, which completely disap-
pears although it does not shift. As discussed below, this dis-
crepancy indicates a complex binding mechanism. 
Titration of CPR into hHO-2 by NMR — If the effects of CPR on the 
hHO-2 spectrum are due to CPR binding, changes induced by 
CPR should be titratable. Thus, additional experiments were 
conducted with 50, 150, 200, and 300 μm CPR, and the reso-
nance height ratio was calculated as described above (Figs. 8 
and 9). Under these conditions, using hHO-2 that was not per-
deuterated, we observed 165 cross-peaks in the 1H-15N hHO-2 
spectrum, which accounts for resonances arising from ~60% 
of the hHO-2 residues. Comparison of these spectra with the 
assigned spectrum allows for assignment of 36% of 288 HO-2 
residues (Figure 9). 
To quantify the effects of CPR on hHO-2 residues, we com-
pared the 1H-15N TROSY spectrum of hHO-2 in the presence 
of CPR to that of hHO-2 alone. Although the addition of CPR 
to hHO-2 does not cause observable changes in hHO-2 chemi-
cal shifts in the TROSY spectrum for non-perdeuterated hHO-
2, a decrease in peak intensity for a number of hHO-2 residues 
proportional to the concentration of CPR is observed (Figure 
9). Although titratable changes in the HO-2 spectrum could 
conceivably result from CPR-dependent catalytic activity of 
HO-2, this is unlikely to be the cause of the observed inten-
sity changes because NADPH is not present in the NMR ex-
periment and HO-2 is inactive in its absence. Furthermore, 
CPR causes similar peak height reduction for the apoHO-2 
Figure 4. Effect of CPR on hHO-2 chemical shifts. Histogram bars represent the combined 15N/NH chemical shift perturbation (CSP) for assigned residues 
in the hHO-2 spectrum in the presence of 75 or 150 μm CPR (white or gray, respectively). The CSP for the assigned cross-peaks, measured between the 0 μm 
CPR spectrum and the 75 or 150 μm CPR spectrum, was calculated from the square root of the sum of the squared N1H and 15N CSPs. Cross-peaks that have 
broadened beyond detection with the addition of CPR are shown as black bars of uniform height. Dotted lines indicate CSPs that are significant (1 standard devi-
ation from the mean) or very significant (2 standard deviations from the mean). Bars with gray labels represent resonances that are unassigned, and assigned res-
idues are in black. 
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spectrum, here substrate and reducing equivalents are both 
absent, preventing any catalytic turnover. 
Of the assigned residues in the hHO-2 spectrum, the res-
idue that is most affected by the addition of equimolar con-
centrations of CPR is Leu-201. Glu-107, Ala-208, Leu-209, Leu-
211, and Leu-33 are also strongly affected. Although in our 150 
μm NMR sample we do not have consecutive assignments for 
these residues, in the more concentrated multidimensional ex-
periments used for assigning the hHO-2 spectrum Leu-201, 
Ala-208, Leu-209, and Leu-211 are part of a consecutively as-
signed region Glu-190–Asn-212. Leu-33 is part of a consecu-
tively assigned region from Arg-29–Leu-37 and Glu-107 is part 
of a consecutively assigned region from Glu-107–Leu-109, so 
the assignments are quite secure. 
We also conducted 15N T2 and T1 relaxation experiments to 
estimate the molecular mass of hHO-2 under the NMR con-
ditions. The rotational correlation time of a protein is lin-
early related to its molecular weight; therefore, 15N spin re-
laxation rates can be used to determine the molecular weight 
of a protein in solution (58). The molecular mass estimate for 
the hHO-2 core was found to be 55 kDa. The mass of mono-
meric hHO-2(1–288) is 33 kDa and that of the hHO-2 core (29–
242) is 25 kDa. Thus, the NMR relaxation experiments indicate 
that hHO-2 is a dimer under the present conditions (>40 μm 
protein). 
NMR Analysis of the Interaction between apoHO-2 and CPR — To 
test the ability of CPR to bind apoHO-2, the 1H-15N spectrum 
of 500 μm non-perdeuterated 15N-apoHO-2 was collected in 
the presence or absence of 100 μm CPR, as described for hHO-
2. The addition of CPR to apoHO-2 causes a loss of intensity 
for apoHO-2 cross-peaks similar to what is observed in the 
hHO-2 spectrum (Figure 10). In the apoHO-2 spectrum, 121 
distinct cross-peaks are visible, representing ~40% of HO-2 
residues. Although assignments for the apoHO-2 spectrum 
have not been determined, changes in chemical shift inten-
sity were quantified by calculating the chemical shift height 
ratio (+CPR/−CPR) for each of the cross-peaks. Of the 121 dis-
tinct cross-peaks analyzed in the apoHO-2 spectrum, 19 ex-
hibit a chemical shift height ratio of less than 0.8, indicating a 
loss of cross-peak height for the corresponding HO-2 residues. 
Changes in chemical shift are not observed for any cross-peaks 
in the non-perdeuterated spectra. These data indicate that CPR 
is capable of binding apoHO-2 as well as hHO-2. 
Assignments have not been independently determined 
for the apoHO-2 TROSY spectrum, and the spectrum is dis-
tinct from that of hHO-2 (Figure 11). However, some isolated 
cross-peaks of the hHO-2 spectrum have identical chemical 
shifts as in the apoHO-2 spectrum, allowing for a reasonable 
assignment of the apoHO-2 cross-peak from the hHO-2 spec-
trum, notably Leu-201 (Figure 11). Strikingly, of the 121 cross-
peaks analyzed, the cross-peak at the location of Leu-201 in 
the apoHO-2 spectrum is the most sensitive to the addition of 
CPR, similar to what was observed for the hHO-2 spectrum. 
Steady-state Kinetic Analysis of HO-1 and HO-2 Mutants — Resi-
dues that exhibit large changes in the hHO-2 NMR spectrum 
upon binding CPR could be present at the interface of HO-2 
and CPR, or alternatively, they could change their chemi-
cal environment due to long range conformational changes in 
HO-2 induced by CPR binding at a distant site. Based on the 
hypothesis that mutation of residues at the HO-2/CPR inter-
face would lead to an increase in Kd values for the HO-2· CPR 
complex and, thus, an increased Km value for CPR, we tested 
the effect of alanine substitutions on steady-state kinetic pa-
rameters for Leu-201 and Lys-169, which were expected to ex-
hibit higher Km values, and Arg-87, which was used as a con-
trol. If a residue exhibits changes in the NMR spectrum by 
indirect effects (e.g. due to a conformational change), making 
a conservative mutation of that residue is unlikely to affect the 
Kd or Km values. Also, we note that HO-2 is likely a homodi-
mer in the NMR binding studies. If a resonance is affected by 
a change in HO-2 dimerization state, a mutation of that resi-
due would be unlikely to affect the kinetic parameters of HO-2 
and CPR. 
Alanine substitution of the HO-2 residue with the cross-
peak intensity that is most strongly affected by equimo-
lar CPR in the non-perdeuterated NMR binding studies (Fig-
ure 9), L201A, results in a 3-fold increase in the Km for CPR 
and no change in kcat compared with wild type protein (Figure 
12B and Table 1). However, the R87A variant of HO-2, whose 
NMR cross-peak height is not strongly affected by the addi-
tion of CPR, exhibits no change in the kcat or Km values for CPR 
(Figure 12B and Table 1). These results are consistent with a 
role for Leu-201 at the binding interface for CPR. 
We also studied the K169A variant of HO-2 because alanine 
substitution of Lys-149, the analogous residue in HO-1, exhib-
its a 7–10-fold increase in the Kd value of the HO-1· CPR com-
plex (24, 27). We observe an ~20-fold increase in the Km value 
of the K169A variant of HO-2 for CPR (Figure 12B, Table 1) 
and a 40-fold increase in the Km value for the K149A variant of 
HO-1 (Figure 12A and Table 1). These results indicate that this 
lysine residue of HO-2 and HO-1 is involved in binding CPR. 
Gel Filtration Analysis of the Binding of hHO-1, hHO-2, and CPR — 
In an attempt to observe the complex between CPR and HO-2 
(and HO-1) by other methods, we performed gel filtration ex-
periments. Kd values ranging from ~0.5 to 2.0 μm have been re-
ported for hHO-1 and CPR, and NADP+ is reported to enhance 
Figure 5. CPR-induced CSPs on the hHO-2 spectrum mapped onto 
the crystal structure. The effect of 75 or 150 μm CPR (A and B, respec-
tively) on hHO-2 CSPs as determined in Figure 4 was mapped onto the crys-
tal structure of hHO-2 (PDB 2QPP). The color of the residue reflects the de-
gree of CSP effect by CPR. Red indicates residues with highly significant CSPs 
(more than two standard deviations from the mean); orange indicates resi-
dues with significant CSPs (at least one standard deviation from the mean); 
blue indicates residues with no significant CSP; white indicates residues that 
are broadened beyond detection; gray indicates residues that are unassigned. 
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binding (24, 27). We performed gel filtration experiments with 
50 μm HO-1 or HO-2 and equimolar CPR in the presence of 
150 μm NADP+ and 150 μm heme. For comparison, the elution 
of the individual proteins (HO-1, HO-2, and CPR) in the pres-
ence of heme and NADP+ was also determined. Because heme 
or NADP+ could affect the migration of the individual proteins, 
they were included in 3-fold excess in all samples. 
By gel filtration analyses, we did not observe any evidence 
for a complex between CPR and either hHO-1 or hHO-2 (Fig-
ure 13 and Table 2). CPR migrates at position 1 (~70 kDa) 
in the absence (dashed line) or presence (red lines) of hHO-1 
or hHO-2 (Figure 13). Peak 2, which marks the migration of 
hHO-2 or hHO-1, corresponds to ~60 and 44 kDa, respectively, 
and shows up as a shoulder in Figure 8A in the HO-1/CPR 
sample. Consistent with the NMR relaxation studies, these re-
sults suggest that hHO-2 exists as a homodimer under these 
conditions. The difference in apparent mass between HO-1 
and CPR is greater than that between HO-2 and CPR; there-
fore, peaks 1 and 2 are slightly separated in Figure 13A and 
are overlapped in Figure 13B. The elution profiles of CPR were 
unaffected by incubation with either HO-1 or HO-2; for exam-
ple, a CPR· HO-2 complex, which would have eluted at a po-
sition corresponding to ~100 kDa, was not observed. Others 
have also failed to observe a complex between wild type HO-1 
and CPR by gel filtration (26). The HO· CPR complex is unde-
tected under these conditions, suggesting that the complex is 
weak and/or highly transient, consistent with the NMR and 
steady-state kinetic studies. 
Binding of CPR to HO-1 or HO-2 by Surface Plasmon Resonance 
(SPR) — We also attempted to quantify CPR binding to HO-1 
and HO-2 using SPR, with HO-1 or HO-2 immobilized on the 
Figure 6. Effect of CPR on perdeuterated hHO-2 chemical shift intensities. Histogram bars represent the ratio of peak height in the absence or pres-
ence of CPR (+CPR/−CPR). Ratios with 75 and 150 μm CPR are shown (white and gray, respectively). A ratio of 1 (dotted line) indicates no change for that resi-
due. Negative bars represent cross-peaks that are broadened beyond detection with the addition of CPR. Bars that are absent represent residues that are unas-
signed in the spectrum. 
29846 s p e n c e r e t  a l . i n t h e j o u r n a l  o f  b i o l o g i c a l  c h e m i s t ry  289 (2014) 
dextran surface of the SPR chip through amine chemistry (Fig-
ure 14). Representative association and dissociation curves 
with various concentrations of CPR (1.25–20 μm) are shown 
in Figure 14A. The SPR sensorgrams show CPR-dependent as-
sociation and CPR-independent dissociation phases, clearly 
demonstrating that CPR binds to both HO-1 and HO-2. To 
avoid potential artifacts, these experiments were performed 
in the absence of heme because heme itself produced a strong 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“binding” response (Figure 14E). Use of the apoproteins is 
justified by our NMR experiments (above) using apoHO-2 
and CPR, which clearly demonstrate that CPR can bind both 
apoHO-2 and hHO-2. 
To derive binding kinetic constants from the SPR sensor-
grams, the association and dissociation phases were fit indi-
vidually because simultaneous global fitting analysis of CPR 
association and dissociation curves using the 1:1 Langmuir 
model (BIAevaluation) produces a poor fit to the data. Single 
exponential fits of the association phase (GraphPad Prism6) 
of CPR and HO-1 or HO-2 were used to determine kon val-
ues (0.0010 ± 0.0002 and 0.0014 ± 0.0002 s−1 μm−1) and koff val-
ues (0.020 ± 0.003 and 0.0230 ± 0.0003 s−1) for CPR binding to 
HO-1 or HO-2, respectively (Figure 14, B and C). From these 
kon and koff values, the Kd values of 20.5 ± 7.6 and 16.7 ± 2.5 
μm were determined for CPR and HO-1 or HO-2, respectively, 
indicating that these proteins form relatively weak (transient) 
complexes. Biexponential fits of the dissociation curves (Fig-
ure 14D) indicate a fast and slow dissociation phase, with kfast 
values in reasonable agreement with the values determined 
by linear regression analysis of the binding data (kfast = 0.026 ± 
0.002 and 0.035 ± 0.008 s−1; kslow = 0.0030 ± 0.0015 and 0.0025 ± 
0.0005 s−1 for HO-1 and HO-2, respectively). 
Sedimentation Velocity Analysis of HO-2 and CPR — Binding inter-
actions between CPR and HO-2 were also analyzed by sedi-
mentation velocity ultracentrifugation, a method that is less 
sensitive to heme artifacts than SPR. As described under “Ex-
perimental Procedures,” 20.5 μm CPR was titrated with vary-
ing concentrations of heme-bound HO-2 (0–55 μm). In these 
experiments, the sedimentation coefficient distribution of CPR 
was monitored in the presence of increasing concentrations of 
hHO-2. Figure 15A shows a sedimentation velocity profile ob-
tained with a 2:1 molar ratio of hHO-2 to CPR. In the absence 
Figure 7. CPR induced changes for hHO-2 cross-peak intensities 
mapped onto the crystal structure. The effect of 75 or 150 μm CPR 
(A and B, respectively) on hHO-2 cross-peak heights mapped on to the crys-
tal structure of hHO-2 (PDB 2QPP). Cross-peak intensity ratios are as de-
termined in Figure 6. The color of the residue reflects the degree of effect by 
CPR. Red indicates ratio of 0 < 0.2; orange indicates ratio of 0.2 < 0.3; blue in-
dicates ratio > 0.3; white indicates residues that are broadened beyond detec-
tion; gray indicates residues that are unassigned. 
Figure 8. NMR analysis of CPR binding non-perdeuterated 15N hHO-2. 1H-15N TROSY spectra of 150 μm non-perdeuterated 15N-hHO-2 collected in 
the absence (black) or presence (red) of equimolar CPR. 
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of hHO-2, CPR is characterized by a sedimentation coefficient 
centered at 4.5 S as shown in Figure 15B. hHO-2 alone shows 
two sedimentation coefficients with a major component (60%) 
centered at 2.8 S and a minor component (34%) at 4.2 S. Upon 
adding hHO-2, the shape of the CPR component changes with 
the boundary shifting to a higher sedimentation coefficient. 
The weight-average s value of this fast boundary component 
was determined by integrating the c(s) distribution between 4 
and 7 S. From these data, a Kd of 15.1 ± 6.5 μm was determined 
for hHO-2 and CPR. At the highest hHO-2 concentration, the 
CPR·HO-2 complex was characterized by a weight-average s 
value of 5.2 S. 
Chemical Cross-linking of CPR and HO-1 or HO-2 — We con-
ducted chemical cross-linking experiments to trap the com-
plex between HO-2 and CPR. Because cross-linking is an ir-
reversible reaction, even transient complexes can be detected. 
Because CPR has been reported to bind HO-1 (24–27), we used 
HO-1 and CPR as a positive control. According to the crys-
tal structure (PDB 3QE2), human CPR possesses at least two 
surface cysteine residues, which should be available for cross-
linking. Thus, we utilized the heterobifunctional cross-linker 
LC-SPDP, which contains both an amine and a thiol-reactive 
group. As described under “Experimental Procedures,” af-
ter activating HO-1 or HO-2 and removing unreacted cross-
linker, CPR was added, and the reaction was incubated over-
night at 4 °C. Stable complexes between CPR and HO-1 as well 
as CPR and HO-2 were formed (Figure 16A). A small amount 
of HO-2 homodimer is visible in the HO-2 sample that lacks 
CPR, although, for activated HO-1 alone, no homodimeric 
complex was observed. 
As a negative control, we activated the HOs as described 
above and incubated with a physiologically unrelated cyste-
ine-containing protein, RNase, instead of CPR. RNase (based 
Figure 9. Effect of various concentrations of CPR on non-perdeuterated 15N-hHO-2 resonances. Histogram bars represent the ratio of resonance 
height in the absence or presence of CPR (+CPR/−CPR). Ratios with 50, 150, 200, and 300 μm CPR are shown (black, light gray, dark gray, and white bars, respec-
tively). A ratio of 1 (dotted line) indicates no change for that residue. Bars that are absent (gray labels) represent resonances that are unassigned, and assigned res-
idues are in bold. The asterisk highlights Leu-201 as the cross-peak that is most sensitive to the addition of CPR. 
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on PDB 1RCA) contains eight cysteine residues, four of which 
are surface-exposed. No high molecular weight complex be-
tween RNase A and either HO-1 or HO-2 was observed (Fig-
ure 16B). 
NMR Studies of HO-2 in the Presence of BVR — BVR mediates 
the second step in heme degradation, the conversion of bili-
verdin to bilirubin. HO-1 and BVR are reported to form a com-
plex with a Kd of 0.2 ± 0.1 μm (24, 27). An overlapping bind-
ing site on HO-1 for CPR and BVR has been proposed but with 
the binding sites not identical (24, 25, 27). To our knowledge, 
binding of HO-2 and BVR has not been addressed. 
To attempt to characterize the binding interface between 
HO-2 and BVR, we performed NMR experiments similar to 
those described for HO-2 and CPR. The 1H-15N TROSY spec-
trum of 150 μm non-perdeuterated 15N-hHO-2 was collected 
in the absence or presence of equimolar BVR (not labeled with 
15N). Although CPR induced obvious changes in the hHO-2 
spectrum (Figure 8), the spectrum of hHO-2 collected in the 
presence of BVR is almost identical to that of hHO-2 alone 
(Figure 17). No changes in the chemical shifts are apparent, 
and the majority of assigned resonances exhibit a height ra-
tio (+BVR/−BVR) close to 1, indicating no change (Figure 18). 
These results suggest that under the NMR conditions (150 
μm), BVR binds hHO-2 very weakly, if at all. Experiments 
with 15N-apoHO-2 and equimolar BVR also showed BVR has 
no effect on the apoHO-2 spectrum (data not shown). 
Our NMR binding studies thus suggest that BVR has a 
significantly lower affinity for HO-2 compared with CPR. In 
contrast, others have reported nanomolar Kd values for the 
BVR·hHO-1 complex (27). Because HO-1 and HO-2 are highly 
homologous, our results were unexpected. Thus, other exper-
iments were performed to assess the interaction between the 
HOs and BVR. 
Figure 10. NMR analysis 
of CPR binding apoHO-2. 
1H-15N TROSY spectra of 500 
μm non-perdeuterated 15N-
apoHO-2 collected in the ab-
sence (black) or presence (red) 
of 100 μm CPR. 
Figure 11. TROSY spec-
tra of hHO-2 (black) and 
apoHO-2 (red). 1H-15N 
TROSY spectra of 150 μm 
non-perdeuterated15N-hHO-2 
(black) or 500 μm non-per-
deuterated apoHO-2 (red). The 
cross-peak assigned as Leu-
201 for the hHO-2 spectrum is 
identified. 
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Fluorescence Quenching Experiments Involving BVR-CPM and HO-1 
or HO-2 — One possible explanation for the lack of NMR ev-
idence for an HO-2/BVR interaction is that HO-2 interacts 
differently with BVR compared with HO-1. To address this 
possibility, we repeated the published fluorescence quench-
ing experiments for measuring interactions between HO-1 
and BVR (27), and we performed similar experiments to de-
termine the binding affinity of HO-2 for BVR. In these stud-
ies, BVR was labeled with the thiol-reactive dye CPM to pro-
duce fluorescent BVR upon excitation at 350 nm. Because the 
hHO-1 absorption spectrum overlaps with the emission spec-
trum of BVR-CPM, hHO-1 binding results in fluorescence 
quenching due to FRET processes. Because apoHO has no ab-
sorbance in the 350 nm region, this method can only be used 
to evaluate hHO binding. Plotting the % fluorescence quench-
ing at 455 nm versus hHO-1 concentration produced a binding 
curve (Figure 19A) that fits to a one-site binding model with 
a Kd of 0.25 ± 0.09 μm, almost identical to the previously re-
ported value of 0.22 ± 0.09 μm (27). Similar FRET experiments 
with hHO-2 and BVR (Figure 19B) provided concentration-de-
pendent, saturable binding curves with a Kd of 0.27 ± 0.01 μm. 
These results suggest that BVR binds both HO-1 and HO-2 
with similar high affinity. Equation 3 can be used to estimate 
a Kd value in situations where the concentration of free ligand 
cannot be estimated due to high affinity and near stoichiomet-
ric binding. If HO-2 and BVR have a Kd of ~300 nm (as sug-
gested by the fluorescence quenching results), Equation 3 pre-
dicts 70% of HO-2 should be complexed with BVR under the 
NMR conditions (with 150 μm HO-2 and 150 μm BVR). This 
is clearly inconsistent with the NMR results; therefore, we 
conducted additional experiments to interrogate the source 
of this apparent discrepancy between the NMR and FRET 
experiments. 
Fluorescence Quenching of BVR-CPM by Heme — To attempt 
to resolve the inconsistency between the NMR and fluores-
cence quenching results, we tested the hypothesis that free 
heme, dissociating from HO-2, may be responsible for the 
Figure 12. HO mutants have an increased Km values for CPR. Heme 
oxygenase activity for HO-1 (A) or HO-2 (B) and their respective mutants 
with varying amounts of CPR. Activity was monitored by observing the for-
mation of bilirubin at 468 nm, as described under “Experimental Procedures.” 
Figure 13. HO and CPR analysis by size exclusion chromatography. 
50 μm CPR and HO-1 (A) or CPR and HO-2 (B) were loaded onto a Shodex 
KW-803 gel filtration column individually or in the indicated mixture in the 
presence of 150 μm heme and 150 μm NADP+ in running buffer (50 mm Tris, 
50 mm KCl, pH 7.0). The asterisk represents the retention time for a 100-
kDa protein, and gray arrows mark the position of the molecular weight stan-
dards. Peak 1, CPR; peak 2, heme oxygenase; peak 3, NADP+ and heme; peak 
4, HO-2 aggregate. 
Table 1. Michaelis parameters for HO variants and CPR. Heme 
oxygenase activity was monitored for HO-1 or HO-2 and the indicated 
mutants with varying amounts of CPR as shown in Fig. 12. Specific activity is 
represented as nanomoles of bilirubin/min/mg of HO.
Construct                   Vmax                        Km                          Km
                       nmol min–1 mg–1                 μM                  -fold change
HO-1
WT  370± 12  0.5 ± 0.1  1
K149A  847 ± 64  21.7 ± 2.6  42.4
HO-2
WT  296.9 ± 4.6  0.7 ± 0.1  1
R87A 275 ± 11  0.9 ± 0.1  1.3
L201A  298.2 ± 8.0  2.3 ± 0.2  3.3
K169A  417 ± 37  15.2 ± 2.6  21.7
Table 2. Apparent molecular weight of HO-1, HO-2, and CPR by 
gel filtration. Ve/V0 values for the indicated proteins, blue dextran (V0), B12, 
and protein standards (Bio-Rad) were measured, and the apparent masses 
were determined as described under “Experimental Procedures.”
Protein                                      Ve/V0                             Apparent mass
  Da
HO-1  1.565 ± 0.005  44,000 ± 1600
HO-2  1.525 ± 0.002  60,300 ± 1100
CPR  1.509 ± 0.004  68,600 ± 2000
CPR (with HO-1)  1.507 ± 0.004  69,600 ± 2000
CPR (with HO-2)  1.506 ± 0.002  70,000 ± 1300
EL = 0.5 (E0 + L0 + Kd – ((E0 + L0 + Kd)2 – 4 E0 ∙ L0)
1/2)        (3)
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fluorescence quenching of BVR-CPM. When free heme was ti-
trated into BVR-CPM under conditions identical to those used 
for hHO titrations, there was strong concentration-dependent 
and saturable quenching of BVR-CPM fluorescence (Figure 
19C), indicating a Kd value of 0.037 ± 0.01 μm. These results 
suggest that the fluorescence quenching observed in the FRET 
experiments could be due to the effects of heme binding to 
BVR, or the CPM fluorophore, rather than the HO protein. As-
suming a Kd of 33 nm for HO-2 and heme (17), Equation 3 pre-
dicts that 1 μm hHO-2 will contain ~0.17 μm dissociated heme, 
which is well above the Kd value determined in these exper-
iments. Thus, we suggest that the quenching of BVR-CPM 
fluorescence observed in the titration with hHO-1 or hHO-2 
results from free heme, dissociated from HO, not the HO pro-
tein. We propose that the heme binds to BVR-CPM from solu-
tion and not through direct heme transfer from the heme-HO 
complex to BVR. In fact, our results demonstrate that these 
proteins do not form a complex, dispelling the possibility of a 
protein-to-protein heme transfer. 
The effects of free heme on BVR-CPM fluorescence are con-
sistent with the report that heme binds to BVR and to residues 
290–296 of the BVR C-terminal peptide (KYCCSRK) (36). Fur-
thermore, when we analyzed BVR-CPM by LC MS/MS to de-
termine the location of the CPM label, we identified one CPM 
molecule attached to Cys-204 and another to either Cys-292 or 
Cys-293 of BVR (Figure 20). Because Cys-292 and Cys-293 are 
located on the same peptide in the LC MS/MS analysis, the 
two cysteines were not distinguished by this analysis. 
Although the other surface-exposed Cys (Cys-74) is not ob-
served in this analysis, it is most likely unmodified because 
BVR-CPM has enzymatic activity similar to that of the wild 
type protein (109%). We and others (59) find that mutation of 
Cys-74 in human BVR, or its homolog Cys-73 in rat BVR, ab-
lates enzymatic activity. Additionally, CPM labeling was con-
ducted in the presence of NADP+, which is expected to protect 
the enzymatic cleft from modification. 
Figure 14. SPR analysis of CPR biding HO-1 (left panels) and HO-2 
(right panels). A, various concentrations of CPR (1.25, 2.5, 5.0, 10.0, and 
20.0 μm) were injected against immobilized HO-1 or HO-2. B, single ex-
ponential fits for the association phase of CPR binding HO-1 or HO-2 are 
shown in red. C, single exponential fits were used to determine kobs for the 
association phase of CPR binding HO-1 or HO-2. kon and koff values are de-
rived from the linear regression of kobs (kon = slope; koff = y intercept). D, bi-
exponential fits for the dissociation phase of CPR binding HO-1 or HO-2 
are shown in red. E, various concentrations of heme (0.125, 0.25, and 0.5 μm) 
were injected against immobilized CPR. Data are representative of three in-
dependent experiments. 
Figure 15. Sedimentation velocity analysis of HO-2 and CPR inter-
actions. A, velocity scans selected from analysis of a 2:1 ratio of hHO-2 (41 
μm) to CPR (20.5 μm). Shown are the absorbance data (open circles) fitted 
(solid lines) to the continuous c(s) distribution model. B, sedimentation co-
efficient distributions of CPR (20.5 μm) alone (black trace) and in the pres-
ence of 4.1 μm (brown trace), 10.25 μm (blue trace), 20.5 μm (red trace), 30.75 
μm (purple trace), 41 μm (green trace), and 55 μm HO-2 (gray trace). hHO-2 
alone (41 μm) is shown in magenta. The inset shows the weight-average s 
value plotted versus HO-2 concentration. The data were fit to a single-site 
binding isotherm to yield a Kd value of 15.1 ± 6.5 μm. 
p rot e i n/p rot e i n i n t e r ac t i o n s i n t h e m a m m a l i a n h e m e d e g r a dat i o n pat h way   29851
BVR Binding Heme by Optical Absorbance — To further investi-
gate the possibility that the fluorescence quenching of BVR-
CPM by hHO-2 results from the binding of free heme by BVR, 
we titrated BVR with free heme and measured the absorbance 
spectrum. As observed by others (36), BVR alone shows no op-
tical absorbance in the 350–700 nm range; however, in the pres-
ence of heme, we observe the development of an absorbance 
band with a wavelength maximum at 415 nm, indicating that 
free heme binds BVR (Figure 21A). To determine the affinity of 
heme for BVR, 5 μm heme was titrated with BVR, and the ab-
sorbance at 415 nm was measured and fit to a single-site bind-
ing model, yielding a Kd of 220 ± 50 nm (Figure 21B). 
Titration of BVR-CPM with hHO-2 produces strong fluo-
rescence quenching; however, because there is no evidence of 
HO-2/BVR binding by NMR, we hypothesize that heme, not 
HO, is responsible for a large part of the fluorescence quench-
ing. To test whether heme from hHO-2 can bind BVR, we in-
cubated hHO-2 with BVR. Because the absorbance of hHO-2 
is ~10-fold greater than that of heme-bound BVR and because 
the absorbance spectra overlap, hHO-2 was included in the 
reference cuvette for these titrations. Under these conditions, 
with increasing concentrations of BVR titrated into hHO-2, ab-
sorbance at 415 nm also increases. This result supports that 
BVR is capable of binding heme from hHO-2 (Figure 21C). 
Chemical Cross-linking of HO-2 and BVR — The above results 
suggest that HO-2 and BVR either do not interact or that that 
they form a very weak complex. We incubated HO-2, which 
had been activated with LC-SPDP and with BVR, as described 
above for trapping the HO-2· CPR complex. Because HO-1 
and BVR have been reported to form a complex (24, 27), we 
also conducted the experiment with HO-1 as a positive con-
trol. Under conditions identical to those used to stabilize the 
HO-2· CPR complex, a high molecular mass complex of ~60 
kDa was observed by SDS-PAGE for BVR and both HO-1 and 
HO-2 (Figure 16C). 
Because HO-2 and BVR are similar in molecular mass, a 
heterodimer of HO-2 and BVR is not distinguishable from ei-
ther homodimer by size alone. To determine whether BVR is 
directly linked to HO-2 in the cross-linked product, we con-
ducted the cross-linking reaction using HO-2 that retained 
an N-terminal His6 tag (hisHO-2). The cross-linked products 
with hisHO-2 were identical to those with HO-2 by SDS-PAGE 
analysis (data not shown). We then isolated hisHO-2 from 
the cross-linking reaction using Ni-NTA resin and analyzed 
the proteins that associated with the affinity resin by reduc-
ing SDS-PAGE, which was subjected to Western blotting us-
ing antibodies against HO-2 or BVR. Under these conditions, 
the cross-linker undergoes reduction, allowing the proteins to 
migrate at their native size. BVR was found to copurify with 
HO-2 in the cross-linked product (Figure 16D). A control re-
action demonstrated that BVR alone did not associate with the 
affinity resin (Figure 16D). These results demonstrate that an 
HO-2·BVR complex can be trapped by chemical cross-linking. 
To identify the location of the cross-linker in the HO-2·BVR 
complex, we conducted a tryptic digest followed by LC-MS/
MS analysis of the cross-linked product. This analysis identified 
the HO-2 peptide containing Lys-264 (KCPFYAAEQKD) linked 
to the BVR peptide containing Cys-292 and Cys-293 of BVR 
(YCCSR), the same peptide shown earlier to bind heme (36). 
Discussion
In the HO reaction, seven electron equivalents from NADPH 
are transferred to the HO-bound heme via CPR. For rapid 
and efficient electron transfer, the electron donor (flavin on 
CPR) and acceptor (heme of HO-2) should be at optimal ori-
entation and distance, implying that an electron transfer com-
plex is formed during the catalytic cycle. One of the issues we 
have addressed in this paper is the existence and nature of that 
electron transfer complex. One possibility is that HO and CPR 
form a stable complex within which multiple electrons transfer 
from NADPH through the bound flavins (FAD and FMN) on 
CPR to the HO-bound heme as it undergoes oxygenation and 
conversion to biliverdin and CO. The other possibility is that 
HO and CPR encounter each other only transiently and associ-
ate/dissociate multiple times during each catalytic cycle. Simi-
larly, either HO or BVR forms a stable complex, within which 
biliverdin is transferred (perhaps channeled) between the two 
proteins or, as another alternative, remains completely un-
attached as the HO product (biliverdin) is released into solu-
tion and captured by BVR to undergo conversion to bilirubin. 
Figure 16. Chemical cross-linking of HO-2 and CPR. A, heterobifunc-
tional cross-linker LC-SPDP stabilizes a complex between HO-1 or HO-2 
and CPR. B, no complex is trapped for HO-1 or HO-2 with RNase. C, chem-
ical cross-linking also stabilizes a complex between HO-1 or HO-2 and BVR. 
Cross-linking reactions contained 10 μm of the indicated protein. D, reducing 
SDS-PAGE and Western blot of HO-2 pulldown and associated BVR. Lane 1, 
cross-linking reaction; lane 2, HO-2 only; lane 3, BVR only. 
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Based on fluorescence quenching, SPR and acetylation protec-
tion studies, a moderately tight HO-1·CPR complex with a Kd 
value in the ~1 μm range had been identified. However, SPR, 
fluorescence quenching, and acetylation protection assays with 
HO-1 have yielded inconsistent results regarding which resi-
dues form the HO-1/CPR binding interface (24, 25, 27). 
Interactions between HO and CPR — Whether or not HO-2 and 
CPR form a complex has not been previously investigated. As 
a result of spectroscopic (NMR, fluorescence), steady-state ki-
netic, and other biochemical (chromatographic, analytical cen-
trifugation, and SPR) studies, we have obtained novel infor-
mation about the nature of the interactions between these two 
proteins. 
Although our focus is on HO-2, we also analyzed CPR 
binding to HO-1, primarily as a positive control for the HO-2/
CPR studies, as CPR binding HO-1 has been previously de-
scribed (24–27). Consistent with previous reports, we observe 
CPR binding HO-1 by SPR and by chemical cross-linking. 
By gel filtration experiments, under our experimental con-
ditions (50 μm hHO and 50 μm CPR with NADP+), HO-2 ap-
pears to form a homodimer. We do not observe any evidence 
for a complex between HO-2 and CPR. Gel filtration experi-
ments occur under nonequilibrium conditions in which the 
component proteins of any transient complex, once dissoci-
ated from the complex, are unable to reassociate once they are 
in a separate zone of the chromatographic column. However, 
SPR experiments clearly demonstrate CPR binding to HO-2 
(Figure 14). 
SPR is a valuable method for studying protein-protein in-
teractions because the proteins remain in the same solution 
and reach equilibrium; furthermore, one can monitor both the 
rates of association and dissociation. Our SPR results clearly 
demonstrate that CPR binds to both HO-1 (Kd = 20.5 μm) and 
HO-2 (Kd = 16.7 μm) with CPR-dependent rates of association 
and CPR-independent dissociation rates. For HO-1, our results 
give a Kd value that is 10-fold larger than previously reported 
(24). The lower affinity of CPR for HO-1 observed in our stud-
ies could be due to differences in the experimental design; our 
studies were conducted in the absence of heme and utilized 
immobilized HO-1 with human CPR as the soluble analyte, 
whereas earlier studies were conducted with immobilized 
rat CPR with hHO-1 in solution. Although we also observe 
a binding response when we titrate either hHO-1 or hHO-2 
against immobilized human CPR, we found that free heme 
also produces a strong binding response with immobilized hu-
man CPR (Figure 14E) and with immobilized BVR (data not 
shown). Thus, to avoid potential artifacts, these experiments 
were performed in the absence of heme. Our use of the apo-
HOs is justified by our NMR experiments, which clearly dem-
onstrate that CPR can bind both forms (apoHO-2 and heme-
bound) of HO-2. We are unaware of any physiologic rationale 
for heme binding to CPR, so this is likely to be a nonspecific ef-
fect. However, as we discuss below, BVR has previously been 
shown to bind heme and to shuttle heme into the nucleus (36). 
Although by SPR we observe no binding of apoHO to immo-
bilized CPR, the conformation of CPR is critical for HO bind-
ing (26), and it is possible that immobilization of CPR stabi-
lizes a conformation that has a lower affinity for HO. 
Sedimentation velocity experiments also provide evidence 
of a dynamic complex between HO-2 and CPR, with a Kd (15.1 
μm) value that is similar to that calculated from the SPR data. 
The HO-2· CPR complex can also be captured by chemically 
cross-linking an amino group of HO-2 through a 15.7 Å tether 
Figure 17. NMR analysis of BVR binding HO-2. 1H-15N TROSY spectra of 150 μm non-perdeuterated 15N-hHO-2 collected in the absence (black) or 
presence (red) of equimolar BVR. 
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to a surface-reactive Cys residue on CPR. The latter is, of 
course, irreversible and designed to capture even highly tran-
sient interactions. 
The NMR experiments also show that an interaction be-
tween HO-2 and CPR occurs. The primary proof is the over-
all and large loss of peak intensity for the core resonances, 
due to broadening associated with the large increase in time-
averaged molecular weight. In addition, excess peak inten-
sity loss due to exchange broadening and CSP occurs for sev-
eral but not all signals. The latter observations are compatible 
with specific binding and with binding kinetics that are on 
the fast/intermediate NMR shift time scale (koff ~100 s−1). In 
turn, this is suggestive of a Kd value in the low micromolar 
range, consistent with the values of 15 μm as found by ana-
lytical ultracentrifugation experiments and 16.7 μm as found 
by SPR. Regretfully, the NMR experiments do not allow a pre-
cise determination of these values, because the NMR signals 
disappear at higher titration stoichiometries, and saturation of 
binding cannot be observed. 
Having assigned ~70% of the resonances in the HO-2 NMR 
spectrum, we used the CSPs to identify the HO-2/CPR inter-
face. Titration of perdeuterated 15N-hHO-2 with CPR altered 
the chemical shift of several residues in the hHO-2 NMR spec-
trum. At both 75 and 150 μm CPR, residues of the HO-2 cata-
lytic core exhibit larger CSPs compared with the N and C ter-
mini (Figure 4). Residues that exhibit the largest CSPs with the 
addition of 75 μm CPR are Phe-99, Tyr-202, Leu-66, Lys-89, 
and Glu-190. 
Upon adding CPR, we also observed dramatic and titrat-
able reductions in the intensities of some of the 1H-15N TROSY 
peaks of resonances from the catalytic core domain of HO-2 
(Figs. 6 and 9). The majority of intensity changes due to ex-
change broadening of the TROSY peaks occur in the struc-
tured core region of HO-2, with few intensity changes 
Figure 18. Effect of BVR on HO-2 resonances. The ratio of hHO-2 resonance height with and without equimolar BVR (+BVR/−BVR) is represented by the 
gray bars. A ratio of 1 (dashed line) indicates no change for that residue. Bars that are absent (gray labels) represent resonances that are unassigned, and assigned 
residues are in bold. 
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originating from the dynamically unfolded N (Ser-8) or C ter-
minus (Tyr-268). Chemical shift perturbations induced by CPR 
titrations also affect the core residues of hHO-2, although the 
N and C termini are unaffected (Figure 4). These results indi-
cate that CPR interacts with the catalytic core of the protein 
and has minimal interactions with the N- or C-terminal re-
gions of HO-2. 
Figure 22A highlights residues on hHO-2 that exhibit both 
significant CSPs and large intensity changes with the addition 
of 75 μm CPR as follows: Leu-66, Phe-99, Glu-102, Asp-193, 
Gln-200, Tyr-202, and Leu-209. Strikingly, in the recent HO-1/
CPR crystal structure, residues conserved with HO-2, Phe-99, 
Glu-102, Gln-200, and Tyr-202 form a patch that is at the CPR 
interface (Figure 22B). The HO-1 residue conserved with Asp-
193 is also located at the CPR interface, as are HO-1 residues 
conserved with the HO-2 residues targeted by mutagenesis, 
Leu-201 and Lys-169 (Figure 22). 
Additional HO-2 residues show either significant CSPs with-
out extra intensity change or large changes in intensity with-
out chemical shift changes. Especially the latter phenomenon 
 
 
 
 
 
 
 
 
 
is prevalent for the most affected residue, Leu-201, and is theo-
retically incompatible with a canonical intermediate exchange 
binding process as described by Equation 2. Rather, it is sug-
gestive of additional, significantly populated bound states of 
CPR sensed by Leu-201 that are in intermediate/fast exchange 
with each other and with Leu-201 in the free state. It can be 
shown that the observed broadening without shift can occur 
if the CSPs of the different bound states approximately can-
cel. (E. R. P. Zuiderweg, unpublished data.) The residues af-
fected by this noncanonical mechanism are conserved in HO-
1, where they are located at the interface for CPR (Glu-86, 
Figure 21. Heme binds BVR by optical absorbance. A, absorbance 
spectrum of 2.5 μm BVR with 2.0 μm heme. BVR alone shows no absor-
bance in the 350–700 nm range. B, A414 of 10 μm heme titrated with varying 
concentrations of BVR (0.05, 0.1, 0.2, 0.3, 0.4, 0.6, 0.8, 1.2, 2.0, 3.0, and 5.0 μm 
BVR). Data are fit to a single binding model using GraphPad Prism 6.0. C, 5 
μm hHO-2 alone (dotted line) or titrated with various concentrations of BVR 
(1.0, 2.0, 8.0, 10.0, and 20.0 μm). Samples for BVR titrations contain 5 μm 
hHO-2 in the reference cuvette because the absorbance of hHO-2 is ~10-
fold that of heme-BVR, and the hHO-2 spectrum overwhelms the heme-BVR 
spectrum if it is not subtracted. 
Figure 20. Biliverdin reductase modified by CPM. LC-MS/MS analysis 
of BVR-CPM identifies CPM modification (*) at Cys-280 and either Cys-292 
or Cys-293. Cys-74 was not observed in this analysis. 
Figure 19. Fluorescence quenching of BVR-CPM by heme oxygen-
ases and heme. Titration of heme-bound HO-1 (A), HO-2 (B), or heme 
alone (C) into BVR-CPM. Percent fluorescence quenching plotted against the 
concentration of the titrant and fit to a single binding model to determine 
the Kd of binding using GraphPad Prism 6.0. 
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Asp-90, Glu-190, Leu-201, Arg-203, Ala-208, and Asp-210) or 
in patches of residues adjacent to the interface in (Ala-31, Leu-
33, Leu-36, Leu-37, Leu-81, Glu-107, Lys-89, Asn-88, Leu-149, 
Gln-172, Glu-182, Thr-184, and Thr-215). These residues also 
localize at and around the binding site for HO-2 as identified 
from CSPs alone. The extended nature of the interaction sur-
face would also be compatible with multiple binding modes 
for CPR as implied from the noncanonical broadening. The ex-
istence of multiple bound states, or an ensemble of encounter 
complexes, has been suggested for other electron transfer com-
plexes as well (60, 61). 
NMR relaxation and gel filtration studies indicate that 
HO-2 exists as a homodimer in solution at the conditions 
used. Changes in the homodimerization state of HO-2 upon 
CPR binding could give rise to CPR-dependent changes in the 
TROSY spectrum, and these changes would be difficult to dis-
tinguish from changes induced by CPR binding HO-2 directly. 
However, HO-2 crystallizes as a homodimer, and the HO-2/
HO-2 interface is distant from the majority of the CPR-induced 
changes that occur in the HO-2 TROSY spectrum (Figure 22A). 
This supports that the CPR-induced changes observed in the 
HO-2 TROSY spectrum are not due to changes in the HO-2 di-
merization state but rather CPR directly binding to HO-2. 
There is a major difference between the koff as suggested by 
NMR (~100 s−1) and the value measured by SPR (~0.023 s−1). 
The latter value would give rise to an extremely slow NMR 
shift time scale and would not allow for any of the observed 
chemical shift changes. This contradictory situation is reminis-
cent of the binding of an organic phosphate molecule to he-
moglobin, where, despite an off-rate of 0.01 s−1, fast exchange 
dynamics were observed using 31P NMR. Multiple binding 
sites for the small molecule on the hemoglobin surface were 
proposed to explain the apparent discrepancy, and a mathe-
matical model that recapitulated the experimental results was 
described (62, 63). In this study, we have evidence for the ex-
istence of multiple bound states of CPR. Perhaps the observed 
rate of ~100 s−1 as indicated by NMR is reflective of the ex-
change kinetics between the various bound states. In con-
trast, the off-rate as measured by SPR monitors the complete 
dissociation. 
Although previous reports on the HO-1· CPR complex fo-
cus on charge-charge interactions (from residues that we were 
not able to assign in our NMR spectra), our results provide the 
first evidence that hydrophobic residues may be involved in 
HO/CPR binding. The majority of the residues highlighted in 
the NMR binding studies are involved in interacting with the 
FAD binding domain of CPR (Figure 22). Kinetic results dis-
cussed below concur with these NMR results. 
Our steady-state kinetic analyses support the conclusion 
that the area near the exposed heme binding face in the cat-
alytic core of HO-2 is involved in binding CPR. For exam-
ple, HO-1 and HO-2, which share a high degree of structural 
similarity in their catalytic core region (55), exhibit simi-
lar Km values for CPR (0.5–0.7 μm). Furthermore, alanine 
Figure 22. Interface for CPR on HO-2 defined by NMR and mutagenesis. A, residues in red have both significant CSPs and large intensity ratio changes 
with the addition of 75 μm CPR. Residues of HO-2 that have significant CSPs or large changes in peak intensity ratio with the addition of 75 μm CPR are shown 
in orange. { identifies a patch of residues strongly affected by CPR (Phe-99, Glu-102, Gln-200, Leu-201, and Tyr-202). Leu-201 and Lys-169 were identified by mu-
tagenesis. Side chains are shown as spheres (PDB 2QPP). B, residues identified for HO-2 mapped onto the analogous residues of HO-1 in the published crystal 
structure of the complex of rat HO-1 (gray) and rat CPRΔTGEE (yellow) (PDB 3WKT). Cofactors are as indicated as follows: heme (green), NADP+ (blue), FAD 
(purple), and FMN (orange). 
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substitution of the core residues that are proposed to be at 
the HO/CPR interface, Lys-169 (or Lys-149 in HO-1) and 
Leu-201, results in significant increases in the Km value for 
CPR. K169A, for example, exhibits a 20-fold increase in Km 
for CPR, in close agreement with prior SPR (24) and acetyla-
tion protection assays (25) but in contrast with earlier FRET 
measurements, which showed no effect of Ala substitution at 
that site (27). The K169A variant of HO-2 also exhibits a 1.4-
fold increase in Vmax, and the K149A variant of HO-1 exhibits 
a 2.2-fold increase in Vmax suggesting that lowering the affin-
ity for CPR increases the steady-state rate under saturating 
substrate (NADPH, O2, and CPR) concentrations. That the 
K149A variant binds heme with identical affinity as the wild 
type (24) and does not exhibit a decrease (instead a slight in-
crease) in Vmax supports our conclusion that its increase in Km 
for CPR reflects disruption of a key interaction between CPR 
and HO-2, not some major disruption in the overall structure 
or at the active site. 
The HO reaction involves many steps, including heme 
binding, seven steps of electron transfer, 3 mol of oxygen 
binding, oxygen activation, biliverdin release, etc. It is ac-
cepted that the rate-limiting step in the HO-1 catalytic cy-
cle when BVR is present is the ring opening of Fe(II)-verdo-
heme (40, 64). However, it is possible that this lysine variant 
is rate-limited by another step. The details of the catalytic cy-
cle for HO-2 or for this variant have not been characterized. 
However, given that K149A (HO-1) and K169A (HO-2) ex-
hibit a 1.4–2.2-fold increase in Vmax and a 20–40-fold increase 
in Km for CPR, it seems reasonable to speculate that, at saturat-
ing concentrations of CPR, the rate-limiting step for this lysine 
variant is electron transfer from CPR to the heme. 
Taken together, our results suggest that during the multi-
step HO-2 reaction, a transient complex between HO-2 and 
CPR forms and dissociates rapidly and that the productive 
electron transfer complex includes HO-2 residues Leu-201 
and Lys-169. The transient nature of the interactions between 
HO-2 and CPR is likely to be an important catalytic feature, 
especially in this and other systems where multiple electrons 
must be passed during each catalytic cycle. 
Our results indicate that a similar dynamic and transient 
binding scenario exists with HO-1. Our gel filtration and SPR 
results indicate that HO-1 (like HO-2) forms a rather weak 
complex with CPR. The transient nature of these interactions 
between HO and CPR is likely to be important in the HO 
mechanism, which requires seven electrons to be transferred 
from NADPH through the redox centers on CPR. 
The catalytic core, shown clearly to be the domain of HO-2 
that interacts with CPR, is highly homologous with HO-1. For 
example, catalytic core residues with NMR resonances most 
strongly affected by CPR that exhibit both CSPs and broaden-
ing (Leu-66, Phe-99, Glu-102, Asp-193, Gln-200, Tyr-202, and 
Leu-209) or with binding constants affected by mutagenesis 
(Lys-169 and Leu-201) are highly conserved between HO-1 
and HO-2. All of those residues are strictly conserved except 
Leu-66 (Gly-46 in HO-1). Earlier reports identified Lys-149 of 
HO-1 to be important in binding CPR (24, 25). It was shown 
that CPR prevents acetylation of that Lys residue and that sub-
stitution of Ala at that position results in a 7-fold decrease in 
affinity for CPR. We found that the K149A substitution results 
in a 40-fold increase in Km for CPR (20-fold for the analogous 
K169A mutation in HO-2). Thus, it appears that both HOs in-
teract similarly with CPR. 
Our results support that HO-2 forms a highly dynamic 
complex with CPR at an interface that includes HO-2 residues 
Leu-201 and Lys-169, and the CPR interface is likely highly 
conserved for both HO-1 and HO-2. As shown in Figure 22B, 
the homologous residues in HO-1 (Leu-181 and Lys-149) are 
located at the HO-1/CPR interface in the crystal structure of 
a complex between HO-1 and a deletion variant of CPR (CPR 
ΔTGEE) (26). This CPR variant forms a stable complex with 
HO-1 that, unlike the wild type protein, can be observed even 
by gel filtration (26). Given the high homology of the struc-
tures of the catalytic cores of HO-1 and HO-2 (55), we suggest 
that Leu-201 and Lys-169 of HO-2 participate in stabilizing the 
electron transfer complex between HO-2 and CPR. 
Interactions between HO and BVR — Based on prior fluores-
cence quenching studies, HO-1 and BVR were proposed to 
form a high affinity complex (27), and our goal was to char-
acterize the analogous HO-2·BVR complex using various bio-
chemical and biophysical methods. However, addition of BVR 
to 15N-labeled hHO-2 results in no chemical shift perturba-
tion and, of the 104 assigned resonances in the hHO-2 spec-
trum, only five exhibit a BVR-dependent decrease in intensity. 
Of those residues that exhibit sensitivity to BVR, three are on 
the surface of the crystal structure and could reasonably be in-
volved in binding BVR (Lys-176, Gln-196, and Tyr-229) (Fig-
ure 18). In contrast, under the same conditions with equimolar 
CPR, 48 of the assigned HO-2 resonances exhibit strong CPR-
dependent effects (Figure 9). These results suggest BVR binds 
hHO-2 with a weak affinity compared with CPR. 
Because the TROSY experiments indicated that HO-2 does 
not bind BVR with high affinity (Figure 18), we repeated the 
original fluorescence quenching studies that described the 
hHO-1· BVR complex (27). Although our results with hHO-1 
are nearly identical to those described in the original paper, 
additional controls indicate that free heme strongly quenches 
BVR-CPM fluorescence independently of HO. We also used 
optical absorbance methods to verify the ability of BVR to 
bind heme, as was reported previously (36). The Kd value 
for the heme· BVR complex differs between the two exper-
iments, with the absorbance data indicating binding of more 
than heme to BVR. Furthermore, labeled BVR contains fluoro-
phores at two specific sites (Cys-292 or Cys-293 and Cys-204). 
We suggest that the fluorescence quenching studies may mon-
itor binding of one heme to BVR at a high affinity site near one 
of these fluorophores, although the optical absorbance studies 
may reflect multiple heme binding events. 
Thus, the fluorescence quenching studies aimed at study-
ing interactions between HO-2 and BVR actually report on 
binding of heme in solution that has dissociated from hHO, 
rather than direct interactions between hHO and BVR. In fact, 
detection of an HO· BVR complex requires the use of methods 
like chemical cross-linking, where even transient complexes 
can be trapped. 
This result describing the low affinity of HO for BVR is im-
portant because it clarifies the mechanism by which BVR cou-
ples to the HO reaction. It has been shown that BVR changes 
the rate-limiting step of the HO-1 reaction from biliverdin re-
lease to the conversion of the Fe2+-verdoheme intermedi-
ate to Fe3+-biliverdin (40). We had taken this to indicate the 
possibility that biliverdin is channeled between the two pro-
teins. However, it now appears that the effect of BVR on the 
HO rate-limiting step occurs by kinetic coupling of the HO 
and BVR reactions, not substrate channeling. BVR binds HO-2 
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very weakly; therefore, substrate channeling, which requires a 
stable complex, is unlikely. Thus, BVR simply binds the bili-
verdin upon release from its product complex with HO, en-
hancing the HO reaction by affecting the mass balance. 
Conclusions — In conclusion, we show that protein· protein 
complexes between HO-2 and other proteins in the heme deg-
radation pathway (CPR and BVR) are highly transient. HO-2 
and CPR form a transient electron transfer complex and, like 
other electron transfer pairs, HO-2 and CPR may form an en-
semble of complexes that is in equilibrium with the productive 
electron transfer complex. NMR binding studies and mutagen-
esis of HO-2 highlight an interface for CPR on HO-2, which is 
consistent with what has been described for CPR and HO-1. 
However, in contrast to studies with CPR and HO-1, our re-
sults suggest that CPR binding HO-2 in solution is dynamic. 
Gel filtration and ultracentrifugation studies support a weak/
transient CPR· HO-2 complex. Complex formation between 
HO-2 and BVR is undetected, except via irreversible binding 
(cross-linking) methods. In the cell, CPR is an electron donor 
for many biologically important reactions. The dynamic inter-
actions between CPR and HO-2 revealed in these studies may 
play an important role in the regulation of the HO system in a 
cellular context. 
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